Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Optic nerve diseases

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    95 result(s) found for: Optic nerve diseases. Displaying page 3 of 5.
    « Previous 1  2  3  4  5  Next»
    EudraCT Number: 2021-006752-14 Sponsor Protocol Number: DualActionWeightLossinIIH1 Start Date*: 2022-08-23
    Sponsor Name:Rigshospitalet, Neurologisk afdeling
    Full Title: Glucagone Like Peptide-1 Receptor (GLP-1R) Analogue Assisted Rapid Weight Loss Program as treatment of Idiopathic Intracranial Hypertension
    Medical condition: Idiopathic Intracranial Hypertension (IIH) is a disease in which the intracranial pressure is pathologically elevated. This can cause blindness, chronic, severe headache, and cognitive dysfunction....
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10004277 Benign intracranial hypertension LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-000529-30 Sponsor Protocol Number: 33 Start Date*: 2013-11-27
    Sponsor Name:Walton Centre Foundation Trust
    Full Title: A pilot study to assess efficacy of prolonged-Release oral fampridine on ambulation and visual function in Neuromyelitis Optica
    Medical condition: Neuromyelitis optica (NMO)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005213-22 Sponsor Protocol Number: SUPREMES-01 Start Date*: Information not available in EudraCT
    Sponsor Name:Charite Universitätsmedizin Berlin
    Full Title: SUPREMES - Sunphenon in progressive forms of multiple sclerosis
    Medical condition: primary and secondary progressive forms of multiple sclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-006718-10 Sponsor Protocol Number: Alcon SMA-08-16 Start Date*: 2009-08-17
    Sponsor Name:Alcon Laboratories, Inc.
    Full Title: The Efficacy and Safety of Travoprost 0.004% versus Tafluprost 0.005% in Primary Open-Angle Glaucoma or Ocular Hypertensive Patients.
    Medical condition: primary open-angle glaucoma ocular hypertension pigment dispersion glaucoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003145-99 Sponsor Protocol Number: CCMROne Start Date*: 2015-03-19
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
    Full Title: A randomised placebo-controlled study of the safety and tolerability of a retinoid-X receptor agonist's ability to promote remyelination in people with relapsing-remitting multiple sclerosis alread...
    Medical condition: Relapsing-remitting multiple sclerosis already on interferon-beta therapy
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-002666-47 Sponsor Protocol Number: SOAP1 Start Date*: 2017-11-02
    Sponsor Name:Dpt. of Ophthalmology, Rigshospitalet-Glostrup
    Full Title: Effect of drop-less surgery compared to topical NSAID alone and combination of steroid and NSAID on central macular thickness after cataract surgery, a randomized controlled trial
    Medical condition: Postoperative cystoid macular edema following cataract surgery
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10070634 Irvine-Gass syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-001982-26 Sponsor Protocol Number: OZM-063 Start Date*: 2018-04-26
    Sponsor Name:The Hospital for Sick Children
    Full Title: A phase II, open-labeled, multi-center, randomized controlled trial of Vinblastine +/- Bevacizumab for the treatment of chemotherapy-naïve children with unresectable or progressive low grade glioma...
    Medical condition: Unresectable or progressive low grade glioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-004459-19 Sponsor Protocol Number: CDRB436G2401 Start Date*: 2019-07-31
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: An open label, multi-center roll-over study to assess long-term effect in pediatric patients treated with Tafinlar (dabrafenib) and/or Mekinist (trametinib)
    Medical condition: Children and Adolescents with Cancers Harboring V600 mutations
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) SE (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-024244-15 Sponsor Protocol Number: RDG-10-251 Start Date*: 2011-07-01
    Sponsor Name:ALCON Research Ltd
    Full Title: "Patient Preference Comparison of Azarga versus Cosopt, in Patients with Open-Angle Glaucoma or Ocular Hypertension."
    Medical condition: Open-Angle Glaucoma and Ocular Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10018307 Glaucoma and ocular hypertension HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005379-10 Sponsor Protocol Number: HUS_MON_2014-01 Start Date*: 2015-05-18
    Sponsor Name:Emiliano Hernández Galilea
    Full Title: Study of tear osmolarity and Quality of Life on patients treated with unpreserved latanoprost 0.005%
    Medical condition: Chronic open angle glaucoma and ocular hypertension
    Disease: Version SOC Term Classification Code Term Level
    17.1 10015919 - Eye disorders 10018307 Glaucoma and ocular hypertension HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005314-29 Sponsor Protocol Number: QTM/OMN-0115 Start Date*: 2016-03-02
    Sponsor Name:OMNIVISION GmbH
    Full Title: Randomized, open-label, two parallel group clinical trial, conducted under blinding evaluator conditions to compare the efficacy and tolerability of preservative-free formulation of Latanoprost 50µ...
    Medical condition: Open Angle Glaucoma or Ocular Hypertension
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004203-39 Sponsor Protocol Number: FNKV-OFT-2013-1 Start Date*: 2014-04-03
    Sponsor Name:Fakultní nemocnice Královské Vinohrady
    Full Title: A randomized, 12 months, active controlled study of the efficacy of repeated doses of intravitreal aflibercept in subjects with prolipherative diabetic retinopathy
    Medical condition: prolipherative diabetic retinopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003853-70 Sponsor Protocol Number: PNRR-MR1-2022-12375914 Start Date*: 2023-05-02
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Towards a personalized precision medicine in rare disease: tirzepatide (a dual glucose­ dependent insulinotropic polypeptide and glucagon-like peptide-I receptor agonist) monotherapy in patients wi...
    Medical condition: Wolfram syndrome type 1
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10078338 Wolfram syndrome PT
    20.0 10010331 - Congenital, familial and genetic disorders 10078338 Wolfram syndrome PT
    20.0 10010331 - Congenital, familial and genetic disorders 10078338 Wolfram syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001781-35 Sponsor Protocol Number: UKER-BC007-01 Start Date*: 2023-05-16
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: Prospective, explorative, randomized, controlled, double-blind, cross-over phase IIa clinical trial to investigate safety and tolerability as well as potential clinical effects of BC007 in patients...
    Medical condition: Post-COVID syndrome
    Disease: Version SOC Term Classification Code Term Level
    24.0 100000004862 10085505 Post-COVID syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016140-39 Sponsor Protocol Number: IDI-GAD-2009-01 Start Date*: 2010-01-19
    Sponsor Name:Institut Diagnostic per la Imatge
    Full Title: MRI in Clinically Isolated Syndromes and relapsing multiple sclerosis after single dose (0.1 mmol/kg) and cumulative dose (0.1 + 0.1 mmol/kg) of GADOVIST at 3.0T Estudio de resonancia magnética 3...
    Medical condition: Realce de contraste en resonancia magnética en pacientes con Síndrome Clínico Aislado o recaída de Esclerosis Múltiple con resonancia magnética anormal anterior después de la administración de dosi...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003528-33 Sponsor Protocol Number: VIB0551.P2.S2.NMO Start Date*: 2022-04-13
    Sponsor Name:Horizon Therapeutics Ireland DAC
    Full Title: An Open-label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Inebilizumab in Pediatric Subjects with Neuromyelitis Optica Spectrum Disorder
    Medical condition: Neuromyelitis optica spectrum disorder (NMOSD; also known as Devic's syndrome and previously known as neuromyelitis optica [NMO])
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10077875 Neuromyelitis optica spectrum disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) SE (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000385-22 Sponsor Protocol Number: RF-2010-2318561 Start Date*: 2014-10-07
    Sponsor Name:Ospedale San Raffaele di Milano
    Full Title: Nerve Growth Factor eye drops as a novel treatment for vision loss in patients with Retinitis Pigmentosa: from preclinical to clinical Phase II trial.
    Medical condition: Retinitis pigmentosa with cystoid macular edema
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004853 10054467 Macular edema LLT
    17.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004157-66 Sponsor Protocol Number: QRK202 Start Date*: 2012-05-29
    Sponsor Name:Quark Pharmaceuticals, Inc.
    Full Title: An Open-Label Dose Escalation Study of PF-04523655 (Stratum I) Combined With A Prospective, Randomized, Double-Masked, Multi-Center, Controlled Study (Stratum II) Evaluating The Efficacy and Safety...
    Medical condition: Diabetic Macular Edema
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) BE (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001572-42 Sponsor Protocol Number: FCN-159-002 Start Date*: 2021-12-21
    Sponsor Name:Shanghai Fosun Pharmaceutical Industrial Development Co.,Ltd.
    Full Title: A multi-center, open-label, single-arm Phase I dose-escalation and Phase II dose-expansion study to evaluate the safety, tolerability, PK characteristics and anti-tumor activity of FCN-159 in adult...
    Medical condition: Participants diagnosed with Neurofibromatosis NF1-related plexiform neurofibromas (PN) and symptomatic with requirement of systematic therapy per investigator’s judgment. A PN is defined as a neuro...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10029270 Neurofibromatosis, type 1 (von Recklinghausen's disease) LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Ongoing) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-024513-31 Sponsor Protocol Number: C-10-041 Start Date*: 2011-06-15
    Sponsor Name:Alcon Research, Ltd.
    Full Title: Efficacy and Safety of Brinzolamide 10 mg/ml / Brimonidine 2 mg/ml Eye Drops, Suspension Compared to Brinzolamide 10 mg/ml Eye Drops, Suspension plus Brimonidine 2 mg/ml Eye Drops, Solution in Pati...
    Medical condition: Patients with open-angle glaucoma or ocular hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10018307 Glaucoma and ocular hypertension HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) PT (Completed) HU (Completed) LT (Completed) DE (Completed) BE (Prematurely Ended) NL (Completed) AT (Completed) ES (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 05:26:22 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA